Lineage Cell Therapeutics, Inc.
LCTX· NYSE
LCTXLineage Cell Therapeutics, Inc.
Filed Aug 9, 2011 · 10-Q · 40 days after period end · 0001140361-11-040659
| Metric | Q2 2011 | Q2 2010 |
|---|---|---|
| Revenue | $780.37K | $680.28K |
| Net Income | -$4.28M | -$2.26M |
| EPS Diluted | -$0.09 | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
ended Jun 30, 2011 · filed Aug 9, 2011 · 40 d after period end
